只使用免费官方源：SEC Forms 3/4/5 结构化内部人申报，以及 FINRA Consolidated NMS 场外卖空成交量。 两类数据均保留来源边界，不转写成买卖建议。
SEC 已完成季度 Forms 3/4/5 结构化历史基线 + EDGAR 当前季度 Form 4 增量；个股卡片仅展示当前自然季度的非衍生证券买卖代码 P/S（公开市场或私下交易），成交金额由股数 × 每股价格计算。
官方数据说明| 2026-07-01 2026-07-06 | LGND LIGAND PHARMACEUTICALS INC | Reardon Andrew Officer · CLO & Secretary | 卖出（S） | 1,119 | US$311.72 | US$348,814.68 | 44,895 | SEC |
| 2026-07-01 2026-07-06 | LGND LIGAND PHARMACEUTICALS INC | Reardon Andrew Officer · CLO & Secretary | 卖出（S） | 1,081 | US$312.28 | US$337,572.95 | 43,814 | SEC |
| 2026-07-01 2026-07-06 | LGND LIGAND PHARMACEUTICALS INC | Reardon Andrew Officer · CLO & Secretary | 卖出（S） | 700 | US$313.46 | US$219,420.18 | 43,114 | SEC |
| 2026-07-01 2026-07-06 | LGND LIGAND PHARMACEUTICALS INC | Reardon Andrew Officer · CLO & Secretary | 卖出（S） | 100 | US$314.58 | US$31,457.88 | 43,014 | SEC |
| 2026-07-01 2026-07-06 | LGND LIGAND PHARMACEUTICALS INC | Reardon Andrew Officer · CLO & Secretary | 卖出（S） | 900 | US$315.78 | US$284,199.75 | 42,114 | SEC |
| 2026-07-01 2026-07-06 | LGND LIGAND PHARMACEUTICALS INC | Reardon Andrew Officer · CLO & Secretary | 卖出（S） | 600 | US$317.15 | US$190,291.02 | 41,514 | SEC |
| 2026-06-16 2026-06-18 | LGND LIGAND PHARMACEUTICALS INC | Sabba Stephen L Director | 卖出（S） | 2,145 | US$254.00 | US$544,830.00 | 33,629 | SEC |
| 2026-06-12 2026-06-15 | LGND LIGAND PHARMACEUTICALS INC | Haas Jason Director | 卖出（S） | 3,461 | US$256.08 | US$886,292.88 | 4,981 | SEC |
| 2026-06-12 2026-06-15 | LGND LIGAND PHARMACEUTICALS INC | Haas Jason Director | 卖出（S） | 3,000 | US$255.01 | US$765,030.00 | 8,442 | SEC |
| 2026-06-11 2026-06-12 | LGND LIGAND PHARMACEUTICALS INC | Aryeh Jason Director | 卖出（S） | 4,500 | US$250.00 | US$112.5万 | 102,580 | SEC |
| 2026-06-10 2026-06-12 | LGND LIGAND PHARMACEUTICALS INC | LAMATTINA JOHN L Director | 卖出（S） | 257 | US$247.22 | US$63,535.54 | 31,303 | SEC |
| 2026-06-10 2026-06-12 | LGND LIGAND PHARMACEUTICALS INC | LAMATTINA JOHN L Director | 卖出（S） | 3,405 | US$251.62 | US$856,766.10 | 26,969 | SEC |
| 2026-06-10 2026-06-12 | LGND LIGAND PHARMACEUTICALS INC | LAMATTINA JOHN L Director | 卖出（S） | 697 | US$249.53 | US$173,922.41 | 30,374 | SEC |
| 2026-06-10 2026-06-12 | LGND LIGAND PHARMACEUTICALS INC | LAMATTINA JOHN L Director | 卖出（S） | 232 | US$248.11 | US$57,561.52 | 31,071 | SEC |
| 2026-06-10 2026-06-12 | LGND LIGAND PHARMACEUTICALS INC | Aryeh Jason Director | 卖出（S） | 500 | US$250.00 | US$125,000.00 | 107,080 | SEC |
| 2026-06-01 2026-06-02 | LGND LIGAND PHARMACEUTICALS INC | Reardon Andrew Officer · CLO & Secretary | 卖出（S） | 491 | US$223.95 | US$109,959.45 | 45,891 | SEC |
| 2026-06-01 2026-06-02 | LGND LIGAND PHARMACEUTICALS INC | Reardon Andrew Officer · CLO & Secretary | 卖出（S） | 677 | US$225.20 | US$152,460.40 | 45,214 | SEC |
| 2026-06-01 2026-06-02 | LGND LIGAND PHARMACEUTICALS INC | Reardon Andrew Officer · CLO & Secretary | 卖出（S） | 1,432 | US$225.97 | US$323,589.04 | 43,782 | SEC |
| 2026-06-01 2026-06-02 | LGND LIGAND PHARMACEUTICALS INC | Reardon Andrew Officer · CLO & Secretary | 卖出（S） | 400 | US$226.78 | US$90,712.00 | 43,382 | SEC |
| 2026-06-01 2026-06-02 | LGND LIGAND PHARMACEUTICALS INC | Reardon Andrew Officer · CLO & Secretary | 卖出（S） | 584 | US$228.57 | US$133,484.88 | 42,798 | SEC |
| 2026-06-01 2026-06-02 | LGND LIGAND PHARMACEUTICALS INC | Reardon Andrew Officer · CLO & Secretary | 卖出（S） | 200 | US$230.41 | US$46,082.00 | 41,382 | SEC |
| 2026-06-01 2026-06-02 | LGND LIGAND PHARMACEUTICALS INC | Reardon Andrew Officer · CLO & Secretary | 卖出（S） | 1,216 | US$229.47 | US$279,035.52 | 41,582 | SEC |
| 2026-05-13 2026-05-14 | LGND LIGAND PHARMACEUTICALS INC | KOZARICH JOHN W Director | 卖出（S） | 1,575 | US$223.50 | US$352,012.50 | 41,786 | SEC |
| 2026-05-12 2026-05-14 | LGND LIGAND PHARMACEUTICALS INC | KOZARICH JOHN W Director | 卖出（S） | 459 | US$224.00 | US$102,816.00 | 41,786 | SEC |
| 2026-05-01 2026-05-14 | LGND LIGAND PHARMACEUTICALS INC | KOZARICH JOHN W Director | 卖出（S） | 1 | US$229.87 | US$229.87 | 42,172 | SEC |
| 2026-05-01 2026-05-14 | LGND LIGAND PHARMACEUTICALS INC | KOZARICH JOHN W Director | 卖出（S） | 165 | US$231.87 | US$38,258.55 | 42,007 | SEC |
| 2026-05-01 2026-05-14 | LGND LIGAND PHARMACEUTICALS INC | KOZARICH JOHN W Director | 卖出（S） | 105 | US$232.57 | US$24,419.85 | 41,902 | SEC |
| 2026-05-01 2026-05-14 | LGND LIGAND PHARMACEUTICALS INC | KOZARICH JOHN W Director | 卖出（S） | 116 | US$234.09 | US$27,154.44 | 41,786 | SEC |
| 2026-05-01 2026-05-14 | LGND LIGAND PHARMACEUTICALS INC | KOZARICH JOHN W Director | 卖出（S） | 80 | US$227.37 | US$18,189.60 | 42,173 | SEC |
| 2026-05-01 2026-05-04 | LGND LIGAND PHARMACEUTICALS INC | Reardon Andrew Officer · CLO & Secretary | 卖出（S） | 98 | US$229.71 | US$22,511.58 | 44,752 | SEC |
| 2026-05-01 2026-05-04 | LGND LIGAND PHARMACEUTICALS INC | Reardon Andrew Officer · CLO & Secretary | 卖出（S） | 370 | US$230.87 | US$85,421.90 | 44,382 | SEC |
| 2026-05-01 2026-05-04 | LGND LIGAND PHARMACEUTICALS INC | Reardon Andrew Officer · CLO & Secretary | 卖出（S） | 1,420 | US$232.92 | US$330,746.40 | 42,182 | SEC |
| 2026-05-01 2026-05-04 | LGND LIGAND PHARMACEUTICALS INC | Reardon Andrew Officer · CLO & Secretary | 卖出（S） | 800 | US$234.02 | US$187,216.00 | 41,382 | SEC |
| 2026-05-01 2026-05-04 | LGND LIGAND PHARMACEUTICALS INC | Reardon Andrew Officer · CLO & Secretary | 卖出（S） | 932 | US$228.75 | US$213,195.00 | 44,850 | SEC |
| 2026-05-01 2026-05-04 | LGND LIGAND PHARMACEUTICALS INC | Reardon Andrew Officer · CLO & Secretary | 卖出（S） | 600 | US$227.45 | US$136,470.00 | 45,782 | SEC |
| 2026-05-01 2026-05-04 | LGND LIGAND PHARMACEUTICALS INC | Reardon Andrew Officer · CLO & Secretary | 卖出（S） | 780 | US$232.04 | US$180,991.20 | 43,602 | SEC |
| 2026-04-01 2026-04-02 | LGND LIGAND PHARMACEUTICALS INC | Reardon Andrew Officer · CLO & Secretary | 卖出（S） | 460 | US$198.85 | US$91,471.00 | 45,922 | SEC |
| 2026-04-01 2026-04-02 | LGND LIGAND PHARMACEUTICALS INC | Reardon Andrew Officer · CLO & Secretary | 卖出（S） | 1,302 | US$199.72 | US$260,035.44 | 44,620 | SEC |
| 2026-04-01 2026-04-02 | LGND LIGAND PHARMACEUTICALS INC | Reardon Andrew Officer · CLO & Secretary | 卖出（S） | 1,238 | US$200.94 | US$248,763.72 | 43,382 | SEC |
| 2026-04-01 2026-04-02 | LGND LIGAND PHARMACEUTICALS INC | Reardon Andrew Officer · CLO & Secretary | 卖出（S） | 700 | US$201.90 | US$141,330.00 | 42,682 | SEC |
| 2026-04-01 2026-04-02 | LGND LIGAND PHARMACEUTICALS INC | Reardon Andrew Officer · CLO & Secretary | 卖出（S） | 963 | US$203.22 | US$195,700.86 | 41,719 | SEC |
| 2026-04-01 2026-04-02 | LGND LIGAND PHARMACEUTICALS INC | Reardon Andrew Officer · CLO & Secretary | 卖出（S） | 337 | US$204.50 | US$68,916.50 | 41,382 | SEC |
| 2026-04-01 2026-04-02 | LGND LIGAND PHARMACEUTICALS INC | KOZARICH JOHN W Director | 卖出（S） | 43 | US$202.91 | US$8,725.13 | 42,412 | SEC |
| 2026-04-01 2026-04-02 | LGND LIGAND PHARMACEUTICALS INC | KOZARICH JOHN W Director | 卖出（S） | 79 | US$202.42 | US$15,991.18 | 42,455 | SEC |
| 2026-04-01 2026-04-02 | LGND LIGAND PHARMACEUTICALS INC | KOZARICH JOHN W Director | 卖出（S） | 40 | US$201.24 | US$8,049.60 | 42,534 | SEC |
| 2026-04-01 2026-04-02 | LGND LIGAND PHARMACEUTICALS INC | KOZARICH JOHN W Director | 卖出（S） | 146 | US$199.97 | US$29,195.62 | 42,574 | SEC |
| 2026-04-01 2026-04-02 | LGND LIGAND PHARMACEUTICALS INC | KOZARICH JOHN W Director | 卖出（S） | 159 | US$204.26 | US$32,477.34 | 42,253 | SEC |
| 代码 | 卖空成交量 | 豁免卖空量 | 场外总成交量 | 卖空量占比 | 报告设施 |
|---|---|---|---|---|---|
| LGND | 77,192.2333 | 0 | 110,189.5668 | 70.05% | B, Q, N |